Navigation Links
GSK Charitable Support Valued at $564 Million in 2007
Date:3/19/2008

LONDON, March 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today reported its 2007 global giving to charitable initiatives totaled $564 million, equivalent to almost 4% of pre-tax profits for the company (with the FTSE 100 average around 1%). Donations of albendazole treatments for the company's flagship program to eliminate Lymphatic Filariasis (commonly known as elephantiasis) were valued at $29 million, bringing the total number of treatments given since GSK made its commitment 10 years ago to almost 750 million.

Commenting on the figures JP Garnier, CEO of GlaxoSmithKline said: "I want GSK to be part of global healthcare solutions, not only through our medicines and vaccines, but also through our public health programs and work with communities. This is embedded in our business, not just an 'add on'; whether it is eliminating LF, supporting HIV communities, fighting malaria, or preventing diabetes. Our partnerships offer more than a helping hand; they are transforming the lives and prospects of people all over the world."

GSK supports health and education programs in more than 100 countries through donations of medicines and through long-term partnerships that provide financial and practical support. The $564 million investment includes product donations valued at $448 million, cash giving of $82 million and other in-kind donations, such as equipment, valued at $6 million. The costs to administer and deliver these programs were $28 million.

The $448 million of product donations included:

-- A continuation of the Lymphatic Filariasis elimination program which

since 1998 has seen the donation of almost 750 million albendazole

treatments by GSK. This program, now in the tenth year of GSK's

involvement working with the World Health Organization and other

partners aims to eliminate LF by 2020.

-- $31 million of humanitarian product donations for the most impoverished

communities and international relief efforts, including the cyclone in

Bangladesh and floods in Mexico. GSK provides significant quantities of

essential quality medicines through a proven crisis response process.

-- $388 million provided via Patient Assistance Programs (PAP) for low

income patients in the USA. GSK provides $1 million in medicines per

day to patients who cannot afford to pay for their prescriptions. These

include products that are able to be used in an outpatient setting

across all therapeutic areas, such as: respiratory, psychiatric,

neurology, metabolic, CV.

Cash donations of $82 million delivered through partnerships with hundreds of charitable organizations.

-- Over $41 million was directed to global and local health programs.

With GSK funding the Malaria Consortium is delivering 'Mobilizing for

Malaria', a program to increase awareness and mobilize resources for

this killer disease. In its 15th year, GSK's Positive Action for HIV

and AIDS delivered effective education, prevention and health care

services in 19 countries. GSK's PHASE (Personal Hygiene And Sanitation

Education) program continues to grow now reaching half a million

school children in 12 countries, helping to prevent diarrhoeal diseases

through better hand-washing.

-- Donations of almost $23 million supported education programs,

including science education and literacy. Through Crest Star

Investigators school children will have access to engaging science

activities at their UK after-school clubs. The target is to reach 5,000

schools and 55,000 children by 2010. GSK's 'Science in the Summer'

enables 6000 children in Philadelphia to participate in hands-on

experiments in libraries. GSK continues to support the Institute for a

Competitive Workforce, a business coalition staffed by the Business

Civic Leadership Center of the US Chamber of Commerce. This is aimed at

improving education and creating a skilled workforce for the future.

In addition to the company donations GlaxoSmithKline employees contributed more than $7 million to charities in the UK and US through employee-organized giving programs. Many also gave their time and skills to their local communities. Further details of GSK's giving and activities relating to other corporate responsibility areas are published today in GSK Corporate Responsibility report on gsk.com.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Virginia G. Piper Charitable Trust and Flinn Foundation launch
2. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
3. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
4. Online Charitable Holiday Giving: Making a Difference with the Gifts You Give
5. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas
6. China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Womens Health Issues
7. MDS Designates Cancer its Major Charitable Cause on World Cancer Day
8. HIV therapy in pregnancy-data support WHO recommendations
9. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
10. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
11. Family-based treatment more effective than supportive psychotherapy in treating bulimia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... Immunotherapy has emerged ... number of cancers and is touted to be the next revolution in our fight ... has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... SAN FRANCISCO , March 29, 2017 /PRNewswire/ ... an option agreement with Bionure Farma, S.L. for ... BN201 and to BN119 in the field of ... million plus sales-based royalties. The agreement provides ... stage assets with a differentiated product profile. Under ...
(Date:3/29/2017)... 29, 2017   Royal Philips (NYSE: ... technology, and PathAI, a company that develops artificial ... aim to develop solutions that improve the precision ... other diseases. The partnership aims to build deep ... of artificial intelligence to be applied to massive ...
Breaking Medicine Technology: